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Abstract 
Background: To evaluate the impact of various measurements of paravalvular regurgitation 
(PVR) on survival after transcatheter aortic valve replacement (TAVR). 
PVR can be difficult to grade and both its incidence and impact on survival may be decreasing 
as TAVR evolves. 
Methods: This retrospective study included 911 patients undergoing TAVR in two institutions. 
PVR was graded according to the 3-grade scheme proposed by the guidelines (PVR grade), 
and subsequently grade 2 and 3, and grade 0 and 1 were lumped together. PVR was also 
graded as a composite score (PVR score), based on 6 commonly used metrics. PVR grade, 
PVR score and its 6 individual components were tested against the risk of both 1-year and 
longer term mortality after TAVR. 
Results: Patients with moderate/severe PVR had a higher STS score, higher levels of serum 
creatinine and larger left atria compared to patients with none/mild PVR. Moderate/severe PVR 
was more frequent with self-expandable and larger valves. After adjusting for ACC TAVR risk 
score, neither PVR grade, PVR score nor its 6 components were associated with an increased 
risk of mortality at 1-year (severe PVR adjusted HR: 0.75, 95% Confidence Interval [CI]: 0.19, 
3.01, p=0.50). However, intervention for clinically severe PVR increased the risk of mortality by 
more than 7-fold (Adjusted HR: 7.6, 95% CI: 2.4, 23.5, p<0.0001). 
Conclusions: In the contemporary era, moderate-severe PVR is uncommon. However, re-
intervention for PVR portends a poor prognosis. This highlights the crucial importance of clinical 
judgment over imaging alone.   
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Introduction 
Transcatheter aortic valve replacement (TAVR) is now considered the standard of care for high-
risk and inoperable patients with severe aortic stenosis (AS), and a valid option also for 
intermediate risk patients since studies comparing TAVR to surgery have demonstrated similar 
results in this group of patients1-3. Many of the feared complications that used to undermine the 
efficacy of this procedure have been significantly overcome by advances in valve sizing, valve 
design, smaller delivery systems and greater expertise of the “heart team”. Among these, 
paravalvular regurgitation (PVR) has been shown to be an important complication of TAVR, 
associated with a 2- to 3-fold increase in mortality when judged severe 4-6. However, a great 
variability in its incidence has been reported so far, varying from 0% to 24% for 
moderate/severe PVR and from 7% to 70 % for mild PVR 7, 8. Such wide ranges could be due 
to: 1) the baseline risk profile of the populations; 2) the type of transcatheter heart valve (THV) 
used (first vs second generation prostheses); 3) the method of assessment of PVR; 4) the 
parameters and criteria relied upon to grade PVR; 5) the type of grading (i.e., 3- vs. 4-class) 
scheme used to classify PVR severity; and 6) the standardization of the assessment of PVR 
(i.e., site vs. core lab reported). Clinically, the echocardiographic assessment of PVR severity 
can be very challenging. Although cine magnetic resonance (CMR) imaging can be used to 
quantify PVR in situations where echocardiography is uncertain or conflicting, we sought to 
compare different echo parameters and grading schemes against outcomes instead. Thus, we 
tested both the guideline-recommended 3- class grading scheme (none/mild, moderate, and 
severe) and a composite PVR score and its individual components on the prediction of the 
survival of consecutive patients undergoing TAVR in our institutions9, 10. The purpose of this 
retrospective study was, therefore, to evaluate the occurrence of PVR (both grade, score and its 
components) and analyze its role on 1-year and long-term survival after TAVR.    
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Materials and Methods 
Study design 
We retrospectively examined 911 patients with severe symptomatic AS undergoing TAVR at 
Baylor Heart and Vascular Hospital (Dallas, TX) and The Heart Hospital Baylor Plano (Plano, 
TX) from January 2012 to July 2016. Baseline demographics, echocardiographic and procedural 
data were retrospectively collected and analyzed. For the purpose of this analysis, data from 
both medical centers were pooled and a joint database was created. Only patients with 
complete echocardiographic information at baseline and post-TAVR were considered for this 
analysis. The severity of PVR was assessed before discharge. Echocardiographic adjudication 
of PVR severity was done by two imaging experts (P.G. and A.S.) who read all the 
echocardiographic exams from both centers. Primary outcome was all-cause mortality at 1-year 
follow-up, which was obtained through querying the National Death Index. As a secondary 
endpoint of interest, long–term mortality was also investigated. The study was approved by the 
Baylor Institutional Review Board. 
Two-dimensional echocardiography 
Transthoracic echocardiography was performed using a commercially available system (iE33 or 
Epiq, Koninklijke Philips Electronics N.V.). Images of the standard parasternal and apical views 
were obtained with th  patient in the left lateral decubitus position. Left ventricular (LV) 
dimensions and function, left atrium diameters were measured according to the current 
guidelines 11. Aortic, mitral and tricuspid regurgitation were quantified according to the most 
recent guidelines 12. 
Using parasternal long- and short-axis, apical and 3 chamber views, the severity of PVR was 
graded according to a 6-metric system, derived from the one proposed by Pibarot et al. in 2015 
9. The metrics included were: 1. Number of jet(s); 2. Jet path visible along the stent; 3. 
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circumferential extension of PVR; 4. Aortic regurgitation index (measured by echocardiography); 
5.Jet density at CW Doppler; 6. Pressure half-time (PHT) (Figure 1 and Supplementary Table 
1). All these metrics were derived from echocardiography. The aortic regurgitation index was 
derived according to the following formula: [(DPB-LVEDP)/SBP] * 100, where DBP is the 
diastolic blood pressure, LVEDP is the left ventricle end-diastolic pressure obtained from the 
end-diastolic velocity of the CW Doppler through the PVR , applying the modified Bernoulli 
equation (4v2) and SBP is the systolic blood pressure (Figure 2). Based on the characteristics 
of these 6 metrics, the PVR severity was graded as none/mild, moderate and severe (PVR 
grade), as suggested by the guidelines 10. Additionally, by giving at each metric a specific 
numeric value, increasing with the severity of the PVR as reported in Supplementary Table 1, 
we were able to obtain a numerical score (PVR score). The PVR grade and score, as well as 
each of the 6 metrics were evaluated for their ability to predict the risk of 1-year and long-term 
mortality.  
Statistical analysis 
 For simplicity, PVR severity was dichotomized (None+Mild versus Moderate+Severe) to 
compare patient preoperative characteristics (Table 1) and procedural characteristics (Table 2).  
Within this dichotomy, unadjusted baseline data were reported and compared using mean(SD) 
and Wilcoxon rank sum tests (which are generally more conservative than t-tests for continuous 
variables) or frequency (%) and exact chi-squared tests.  This dichotomization also helped avoid 
the loss of statistical power due to the low number of patients with severe PVR. To test 
differences in characteristics by dichotomized PVR severity, t-tests were conducted for 
continuous covariates, and chi-squared tests were conducted for categorical covariates. 
For the primary analysis, we pre-specified five logistic regression models using 1-year 
mortality as the dependent (outcome) variable. We specified these five separate models in order 
to determine whether PVR grade, its six individual components, and/or PVR score played a 
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significant role in predicting 1-year mortality after TAVR. The five models tested were: Model 1.) 
6 metrics: The six separate PVR score metrics adjusted for TAVR risk score + any subsequent 
re-intervention/closure; Model 2.) PVR score: PVR score adjusted for TAVR risk score + any 
subsequent re-intervention/closure; Model 3.) PVR grade: Traditional PVR grade adjusted for 
TAVR risk score + any subsequent re-intervention/closure; Model 4.) 6 + PVR grade: The six 
separate PVR score metrics and traditional PVR grade adjusted for TAVR risk score + any 
subsequent re-intervention/closure; Model 5.) TAVR: TAVR risk score only.  Receiver Operating 
Characteristic (ROC) curves for each model were generated and compared using Model 5 as 
the reference and a significance level of p<0.05.  An ROC of 1 indicates a model that perfectly 
predicts 1-year mortality; whereas an ROC of 0.5 indicates a model with no predictive ability (i.e. 
the model does not predict 1-year mortality any better than a simple coin-flip). In all models, we 
treated the six PVR score metrics as continuous variables. Re-intervention/closure was 
dichotomized (yes/no), and PVR grade was categorized as None, Mild, Moderate, or Severe. In 
post-hoc sensitivity analyses, PVR grade dichotomization as none+mild versus 
moderate+severe (rather than four distinct categories) did not meaningfully change model 
results or interpretations. 
We also conducted a secondary analysis using two separate Cox Regression models 
with time-to-death as the outcome to determine whether, after adjusting for TAVR score, either 
1.) PVR score; or 2.) PVR grade were independent predictors of long-term mortality. Again, 
PVR score was treated as a continuous variable and PVR grade was used as a four-category 
variable. In order to avoid the introduction of "immortal-time" bias, patients who died prior to 
discharge were excluded from these analyses.  
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Results 
Study Population 
A total of 911 patients undergoing TAVR between January 2012 and July 2016 had complete 
echocardiographic and survival data and were therefore included in this study. Table 1 displays 
the baseline characteristics for the study population according to the post-TAVR PVR grade. 
Due to the extremely low incidence of severe PVR, grade 2 (moderate) and grade 3 (severe) 
were lumped together. Similarly, grade 0 (none) and grade 1 (Mild) were lumped together as 
there were no differences between them in baseline characteristics or outcomes. Therefore, the 
study population was stratified in two categories: None/Mild (n=875, 96.1%) and 
Moderate/Severe (n=36, 3.9%). The two groups were similar for baseline characteristics, 
although the group of patients with moderate/severe PVR displayed a higher STS score and a 
higher serum creatinine level at baseline. Mean follow-up duration was 40.8±13.9 months. 
Baseline echocardiography  
Patients with moderate/severe PVR had larger left atria at baseline echocardiography. The two 
groups were otherwise similar for the other echocardiographic characteristics. Figure 3 shows 
the incidence of moderate and severe PVR over the years and with the use of different 
prosthesis types.  
Procedural characteristics 
The occurrence of moderate/severe PVR was more frequent with self-expandable valves (Table 
2 and Figure 3B) and with larger prostheses (Table 2). No differences in the incidence of PVR 
were found regarding the prostheses generation or the type of approach. 
PVR and survival  
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As shown in Table 3, none of the five logistic regression models for prediction of 1-year 
mortality after TAVR (n=71/911, 7.8%) was statistically significant. Although the model including 
the 6 metrics + PVR grade (Model 4) had a higher ROC (0.69 vs 0.62) than case mix 
adjustment alone, it, nor any of the other models, was able to add significant predictive utility at 
the p<0.05 significance level for 1-year mortality versus simple TAVR risk score alone (Figure 4 
and Supplementary Table 3). However, PVR characteristics and grading exhibited a non-
significant trend (p=0.06) for prediction of 1-year mortality. In all models, having a re-
intervention/closure increased the risk of mortality by more than 7-fold over baseline risk (Table 
3). We additionally tested the predictive role of PVR score and grade on long-term mortality 
(Table 4). As shown in Table 4, neither PVR grade nor PVR score were significant predictors of 
long-term mortality. Supplementary Table 4 reports detailed data about re-intervention in the 
15 patients that required it. 
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Discussion 
This large retrospective study demonstrated that in the current era, with the advances in valve 
sizing, implant techniques, prosthesis design and experience, the incidence of moderate/ severe 
PVR is low (3.9%) . Probably due to this low occurrence, our study did not find a link between 
significant PVR and 1-year or longer term survival after TAVR. However, re-intervention for PVR 
closure, though uncommon (1.8%), significantly influences mortality.  
PVR has been one of the mostly feared complications since the early phases of TAVR use. 
Over the years, a large body of literature has been published on this topic, showing somewhat 
different results. Early reports showed a prevalence of significant PVR in the range of 20%, with 
2- to 3- fold increase mortality for severe PVR 4, 6, 8, 13, 14. Differences in the grading of the PVR, 
as well as the high risk profile of earlier TAVR populations and in the type of THV used might be 
responsible for the observed discrepancies in the incidence and impact on survival of PVR in 
the various studies 4, 8. In addition, early TAVR experiences were based on echocardiographic 
sizing of the prosthesis, which could have increased the incidence of significant PVR compared 
to the current standard of MDCT sizing 1. Indeed, a huge effort has been put in the development 
of a unifying grading system for PVR. Unlike native aortic regurgitation, the quantification of 
PVR is notably challenging. Shadowing artifact from the prosthesis together with an off-axis cut 
plane of the ultrasound beam might influence significantly how PVR is graded 9. In this study we 
sought to investigate the role of PVR on 1-year and long-term survival after TAVR, by using two 
methods of PVR grading; the first, PVR grade, based on the 3-grade scheme suggested by the 
actual guidelines, and a second, PVR score, based on an adapted version of the scoring system 
proposed by Pibarot et al. in 2015 9. Moderate and severe PVR were subsequently lumped 
together given the paucity of patients in the severe group (n=2). PVR was also graded based on 
6 individual metrics, all of which are derived non-invasively through echocardiography 
(Supplementary Table 1). The results of this study show that, in the current era, the cumulative 
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incidence of significant (moderate/severe) PVR is low and that none of the PVR parameters, nor 
the grade nor the score exerted a statistically significant impact on survival. However, our 
results might have been masked by some factors, notably  limited statistical power; only 2 
patients out of 911 had severe PVR. While this reflects excellent results in the current era, it is 
too small a sample size to exclude the possibility that severe, but not moderate PVR is a 
predictor of outcomes. At this regard, it is worth mentioning that, in our centers, valve sizing is 
based on MDCT which could account for a better sizing algorithm compared to 
echocardiography, and in turn could have led to a lower incidence of significant PVR. Second, 
when the PVR was judged as clinically severe after the implant, our heart team tended toward 
prompt intervention. Therefore, such patients would not be classified as severe PVR on a 
discharge echocardiogram because it had already been alleviated. Indeed, as demonstrated in 
Table 3, patients undergoing a re-intervention or closure of a leak experienced a 7-fold higher 
mortality at 1-year after TAVR. As to why these patients had a bad prognosis, despite early 
correction of severe PVR remains an open question. It is tempting to speculate that their 
baseline risk profile was higher or the post-TAVR hemodynamic deterioration that prompted 
intervention resulted in poor long-term outcomes. However, given the low number of patients 
undergoing re-intervention for severe PVR, it was not possible to perform any meaningful 
statistical analysis. Secondly, it has to be acknowledged that echocardiography is limited in 
assessing PVR, due to the frequent observation of the multiple, irregular, and eccentric 
paravalvular jets and to the difficulties in measuring or unreliability of the quantitative and 
semiquantitative parameters proposed in the American Society of Echocardiography/ European 
Association of Echocardiography guidelines (vena contracta width, jet width to LVOT diameter 
ratio, pressure half-time of the continuous wave Doppler aortic regurgitant envelope) post-
TAVR. This is mainly due to the acute nature of the regurgitation and the reduced compliance of 
the LV. As demonstrated by cardiac magnetic resonance (CMR) studies, there is indeed, a 
great discrepancy between various echocardiographic grading parameters and the regurgitant 
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fraction as measured by CMR 15-17. For this reason, we chose to compare various PVR grading 
parameters to outcomes rather than to an independent quantitative reference standard. Finally, 
we did not include holodiastolic flow reversal in the descending aorta because it was rarely seen 
in our population and has been shown to occur even in the absence of aortic regurgitation 18, 19. 
This parameter is, indeed, influenced by LV and aortic compliance. In particular, low 
transvalvular end-diastolic aorta to LV pressure gradient that is due to concomitant 
moderate/severe LV diastolic dysfunction may lead to false-positive results. The high 
dependency of aortic flow reversal on aortic compliance considerably limits the utility of this 
parameter in the elderly population undergoing TAVR. 9, 18 
The very low incidence of PVR in our study might be the result of the improvement in TAVR 
valve-sizing and the technical experience of the heart team, which, in turn could explain why we 
did not find any impact of PVR on 1-year survival. Consistently, even when looking at longer 
term survival, PVR was not found to be a predictor of mortality when adjusted for TAVR risk 
score. In conclusion, this study shows the occurrence and the prognostic role of PVR in a real 
world scenario. Independently of how PVR is graded, it does not seem to be linked to long-term 
survival after TAVR. However, it has to be acknowledged that the extremely low incidence of 
significant PVR in our population might have masked its own impact on survival. Our results are, 
indeed, in contrast with previous studies showing that PVR was linked to a 2- to 3-fold increase 
in mortality at 1-year after TAVR and this could be explained by the fact that we registered only 
a 4% incidence in significant PVR. 
Finally, when the heart team performs an early re-intervention for PVR, it portends a bad 
prognosis.  
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Conclusion 
Clinical Competencies 
This study might have important implications for current clinical practice. The assessment of 
PVR on echocardiography might be misleading whereas clinical judgment needs to be 
advocated when considering the severity of PVR. In the current era, the occurrence of 
significant PVR is extremely rare and so is the mortality risk connected to this problem. 
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Figure Legends 
Figure 1. Circumferential extension of PVR. Examples of progressively higher circumferential 
extensions of the PVR. 
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Figure 4. ROC curves comparison. ROC curves comparison relative to the 5 models tested 
for the prediction of 1-year mortality. 
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Table 1. Characteristics of the study population according to paravalvular regurgitation 
(PVR) severity at discharge. 
 Paravalvular regurgitation  
 None/Mild 
(n=875, 96.1%) 
Moderate/Severe 
(n=36, 3.9%) 
p 
Demographics    
Age, yrs 81.3±8.0 82.6±8.0 0.325 
Female 410 (46.9) 14 (38.9) 0.348 
Body Mass Index, Kg/m2 27.8±6.7 26.8 ±6.3 0.373 
Body Surface Area, m2 1.9±0.25 1.9±0.24 0.494 
STS score, % 7.7±4.3 9.6±4.8 0.010 
ACC TAVR risk score, % 4.8±2.2 4.7±1.6 0.744 
Cardiac Comorbidities    
Hypertension 757 (86.5) 29 (80.6) 0.309 
Hyperlipidemia  657 (75.1) 26 (72.2) 0.697 
Diabetes 347 (39.6) 12 (33.3) 0.738 
Coronary artery disease 627 (71.7) 26 (72.2) 0.941 
Peripheral artery disease 287 (32.8) 7 (19.4) 0.093 
Atrial Fibrillation 272 (31.1) 12 (33.3) 0.193 
Previous CABG/PCI 424 (48.5) 19 (52.8) 0.611 
Previous CVA 177 (20.2) 7 (19.4) 0.909 
Permanent Pacemaker 176 (20.3) 7 (20.6) 0.962 
Non-cardiac Comorbidities    
Chronic kidney disease 657 (75.1) 30 (83.3) 0.260 
End stage renal disease 27 (3.1) 3 (8.3) 0.084 
Serum creatinine, ml/L 1.34±0.7 1.63±0.8 0.026 
COPD 198 (22.6) 4 (11.1) 0.103 
On Home Oxygen 53 (6.1) 1 (2.8) 0.414 
Myelodysplastic Disease 26 (3.0) 1 (2.8) 0.946 
Liver Disease 15 (1.7) 1 (2.8) 0.634 
Baseline Echocardiographic findings   
LVEF, % 54.7±13.0 52.8±12.9 0.404 
Stroke Volume Indexed, ml/beat/m2 37.6±12.0 36.1±9.7 0.456 
Aortic valve mean gradient, mmHg 44.5±13.7 46.3±14.5 0.444 
Aortic valve area, cm2 0.68±0.18 0.65±0.22 0.402 
Bicuspid aortic valve, % 99/847 (11.3) 4/36 (11.1) 0.989 
Aortic peak velocity, m/sec 4.3±0.61 4.3±0.69 0.725 
Mitral valve mean gradient, mmHg 3.1±2.1 3.4±2.6 0.448 
Mitral Regurgitation ≥2+ 153 (17.5) 7 (19.4)  0.762 
Aortic regurgitation ≥2+ 94 (10.7) 5 (13.9) 0.552 
Tricuspid regurgitation ≥2+ 104 (11.9) 8 (22.2) 0.064 
Systolic Pulmonary Arterial 
Pressure, mmHg 
42.7±14.5 43.6±18.3 0.761 
Left atrial volume, ml 82.7±30.3 109.2±47.9 <0.0001 
Values are mean±SD, n (%). 
Abbreviations: CABG: coronary artery by-pass graft; COPD: chronic obstructive pulmonary 
disease; CVA: cerebrovascular accident; LVEF: left ventricle ejection fraction; PCI: percutaneous 
coronary intervention; SD: standard deviation. 
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Table 2. Procedural characteristics. 
 Paravalvular regurgitation  
 None/Mild 
(n=875, 96.1%) 
Moderate/Severe 
(n=36, 3.9%) 
p 
Type of Valve   <0.0001 
Self-expandable 342 (39.1) 25 (69.4)  
Balloon -expandable 533 (60.9) 11 (30.6)  
Valve Generation   0.657 
First 590 (67.4) 23 (63.9)  
Second 285 (32.6) 13 (36.1)  
Valve Size (mm)   <0.0001 
20 13 (1.5) 0 (0)  
23 191 (21.9) 3 (8.3)  
25 12 (1.4) 2 (5.6)  
26 315 (36.1) 8 (22.2)  
27 12 (1.4) 0 (0)  
29 263 (30.2) 12 (33.3)  
31 62 (7.1) 11 (30.6)  
34 3 (0.3) 0 (0)  
Balloon pre-dilatation 599 (68.5) 20 (55.6) 0.102 
Balloon post-dilatation 419 (47.9) 21 (58.3) 0.219 
Approach   0.177 
Trans-femoral 769 (87.9) 36 (100)  
Trans-apical 69 (7.9) 0 (0)  
Trans-aortic 7 (0.8) 0 (0)  
Subclavian 30 (3.4) 0 (0)  
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Table 3 – Logistic Regression models for the prediction of 1-year mortality 
Characteristic at Discharge: Odds Ratio (95% CI) p-value 
Model 1: 
N Regurg Jet S 
Jet Visible 
Circumferential Extension 
Aortic Regurg Index Score 
Jet Density 
PHT Score 
Reintervention/closure 
 
0.53 (0.25, 1.13)* 
1.62 (0.48, 5.44)* 
1.40 (0.73, 2.68)* 
1.18 (0.72, 1.92)* 
0.52 (0.23, 1.21)* 
1.12 (0.44, 1.86)* 
11.9 (3.6, 39.5) 
 
0.10 
0.44 
0.31 
0.51 
0.13 
0.81 
<0.0001 
Model 2: 
PVR score 
Reintervention/closure 
 
1.00 (0.93, 1.08) 
7.6 (2.4, 23.5) 
 
0.97 
<0.0001 
Model 3: 
PVR grade 
     None 
     Mild 
     Moderate 
     Severe 
Reintervention/closure 
 
 
Reference 
0.72 (0.30, 1.72) 
1.32 (0.77, 2.27) 
0.75 (0.19, 3.01) 
8.3 (2.5, 27.8) 
 
0.50 
 
 
 
 
<0.0001 
Model 4: 
N Regurg Jet S 
Jet Visible 
Circumferential Extension 
Aortic Regurg Index Score 
Jet Density 
PHT Score 
PVR Grade 
     None 
     Mild 
     Moderate 
     Severe 
Reintervention/closure 
 
0.52 (0.24, 1.11)* 
1.28 (0.35, 4.67)* 
1.27 (0.53, 2.56)* 
1.20 (0.82, 1.75)* 
0.49 (0.21, 1.12)* 
1.11 (0.44, 1.83)* 
 
Reference** 
<.01 (<.01, >99.9)** 
<.01 (<.01, >99.9)** 
<.01 (<.01, >99.9)** 
10.9 (3.2, 37.6) 
 
0.09 
0.71 
0.50 
0.35 
0.09 
0.83 
0.60 
 
 
 
 
<0.0001 
*Odds Ratio and 95% Confidence Interval for each 1-point increase in each metric: (i.e. OR for 1 vs 0; 2 
vs 1; 3 vs 2);  
**Due to high correlation between covariates, model estimates for PVR grade are extremely wide 
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Table 4 – TAVR-risk-adjusted long-term mortality 
Characteristic at Discharge: Hazard Ratio (95% CI) p-value 
PVR score* 0.99 (0.93, 1.05) 0.70 
PVR grade* 
     None 
     Mild 
     Moderate 
     Severe 
 
Reference 
0.83 (0.43, 1.60) 
0.95 (0.62, 1.47) 
1.40 (0.56, 3.51) 
0.81 
*adjusted for TAVR risk score 
 
 
